Clinical Trial Update: Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Tripegfilgrastim to reduce severe neutropenia in patients with unresectable pancreatic cancer and unresectable biliary tract c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Tripegfilgrastim (Tripegfilgrastim)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma | Phase 2 | Status: RECRUITING